The device-aided intrajejunal delivery of levodopa–entacapone–carbidopa intestinal gel the treatment of Parkinson’s disease: overview of efficacy and safety

Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG), d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Expert review of medical devices Jg. 22; H. 6; S. 533 - 544
Hauptverfasser: Popławska-Domaszewicz, Karolina, Metta, Vinod, Odin, Per, Chaudhuri, K Ray
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 03.06.2025
Schlagworte:
Antiparkinson Agents - administration & dosage
Antiparkinson Agents - therapeutic use
Carbidopa - administration & dosage
Carbidopa - adverse effects
Carbidopa - therapeutic use
Catechols - administration & dosage
Catechols - adverse effects
Catechols - therapeutic use
Clinical Medicine
Drug Combinations
Drug Delivery Systems - instrumentation
Gels
Humans
Jejunum
Klinisk medicin
Levodopa - administration & dosage
Levodopa - adverse effects
Levodopa - therapeutic use
Medical and Health Sciences
Medicin och hälsovetenskap
Neurologi
Neurology
Nitriles - administration & dosage
Nitriles - adverse effects
Nitriles - therapeutic use
Parkinson Disease - drug therapy
Treatment Outcome
advanced parkinson’s disease
infusion pump
Device-aided therapy
LECIGON
medical device
levodopa–carbidopa–entacapone
ISSN:1743-4440, 1745-2422, 1745-2422
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while levodopa-entacapone-carbidopa intestinal gel (LECIG), delivered via the Crono LECIG pump, is a more recent addition to the range of DAT options in Europe. This article explores the rationale for the development of LECIG infusion, the role of entacapone in the formulation, and the attributes and specifications of the LECIG infusion pump device. Clinical and real-world data reporting its efficacy, safety and tolerability of LECIG in advanced PD patients from a range of European centers are reviewed, with a focus on the practical benefits that a smaller, lighter and quieter device can provide for patients who wish to start treatment with intrajejunal levodopa infusion. LECIG infusion delivered via the LECIG infusion pump offers another valuable DAT option to consider for suitable people with advanced PD providing both good long-term clinical benefits and a favorable treatment experience for patients.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1743-4440
1745-2422
1745-2422
DOI:10.1080/17434440.2025.2499153